Current issues in Hereditary Angioedema (HAE) - Ipopi
Current issues in Hereditary Angioedema (HAE) - Ipopi
Current issues in Hereditary Angioedema (HAE) - Ipopi
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Recent <strong>in</strong>itiatives<br />
• World consensus document published July 2010<br />
– Earlier treatment of acute attacks<br />
– New treatments<br />
• C1 <strong>in</strong>hibitor, icatibant, ecallantide<br />
– FFP (plasma) obsolete<br />
– Lower doses of danazol/stanozolol<br />
– Self adm<strong>in</strong>istration available for everyone who wants it<br />
– http://www.aacijournal.com/content/6/1/22 or 24<br />
• Trials of self-adm<strong>in</strong>istration of icatibant<br />
• Subcutaneous C1 <strong>in</strong>hibitor<br />
• Higher doses of C1 <strong>in</strong>hibitor<br />
• rC1 <strong>in</strong>hibitor for Europe-early 2011<br />
• Ecallantide for Europe- 2011<br />
• USA patient-led database<br />
• Icatibant outcome survey
Change language